Causal associations between plasma proteins and prostate cancer: a 1

2

Proteome-Wide Mendelian Randomization

- Chen Lin^{1#}, Rong Zhuona^{1#}, Gu Yanlun^{1,2}, Chen Yuke³, Yu Wei³, Zhou Ying^{1*}, 3
- Pang Xiaocong^{1*} 4
- ¹ Department of Pharmacy, Peking University First Hospital, Xishiku Street, Xicheng 5
- 6 District, 100034 Beijing, China
- ^{1,2} School of Pharmaceutical Sciences, Peking University, Xueyuan Road 38, Haidian 7
- District, 100191 Beijing, China 8
- ³ Department of Urology Surgery, Peking University Third Hospital, Xueyuan Road 9
- 10 38, Haidian District, 100191 Beijing, China
- *Corresponding author. 11
- 12 #Contributed equally.

Abstract 13

Background: 14

- Due to the limitations in specificity of current diagnostic methods for prostate cancer 15
- (PCa), more reliable biomarkers are needed to explore for improving early detection. 16
- Plasma proteins represent a promising source of biomarkers, therefore understanding 17
- the causal relationships between specific plasma proteins and PCa could be 18
- conductive to identify novel biomarkers and therapeutic targets for PCa prevention 19
- 20 and treatment.

21 **Methods**:

We performed a meta-analysis of two independent genome-wide association studies 22 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

(GWASs) including 94,397 individuals with PCa and 192,372 controls. A mendelian
randomization (MR) supplemented by colocalization analysis was conducted, using *cis*-acting variants on 4,907 plasma proteins from deCODE Genetics (N=35,559) and
2,940 plasma proteins from UK Biobank Pharma Proteomics Project (UKB-PPP)
(N=54,219). Then, the biological pathway analysis and druggability evaluation of the
risk proteins were further performed.

29 **Results**:

Five possible susceptibility loci (JAZF1, PDILM5, WDPCP, EEFSEC, and TNS3) for 30 31 PCa were identified through the meta-analysis of GWASs. Among 3,722 plasma proteins, 193 proteins were associated with PCa risk, of which 20 high-risk proteins, 32 33 including KLK3, were validated in both the deCODE and UKB-PPP cohorts. 34 Functional annotation of these genes encoding proteins confirmed enrichment of immune response, inflammatory response, cell-cell interaction and so on. Genetic 35 colocalization and druggable genome analyses also identified several potential drug 36 37 targets for PCa, such as HSPB1, RRM2B and PSCA.

38 Conclusions:

We identified novel variants as well as several protein biomarkers linked to PCa risk and indicated pathways associated with PCa, which offered new insights into PCa etiology and contributed to development of novel biomarkers for early detection and potential therapeutic interventions.

43 Funding:

44 This work was supported by grants from Beijing Municipal Natural Science

- 45 Foundation (grant No. JQ24059, No. L234038) and National Natural Science
- 46 Foundation of China (grant No. 82274015).
- 47 Keywords: Prostate cancer, Proteins, Biomarkers, Mendelian randomization,
- 48 Colocalization analysis
- 49 **Graphical abstract**: A comprehensive study design summarized as follows.

50 Introduction

Prostate cancer (PCa) is the second most common malignancy with an estimation of 51 52 1.5 million new cases in 2022, which is account for 14% of total cancer diagnosed in men worldwide(Ferlay J, 2024). Even more worrying is that the number of new cases 53 of PCa are projected to 2.9 million by 2040(James et al., 2024). Despite 54 55 advancements in medical technology, early detection of PCa remains a significant 56 challenge due to the limitations in specificity of current diagnostic methods, such as prostate-specific antigen (PSA) testing(Carter et al., 2013; Draisma et al., 2009; 57 58 Oesterling, 1991). Therefore, there is an urgent need for more accurate and reliable biomarkers that can improve early detection and prognostic evaluations of PCa. 59 Plasma proteins have key roles in the development and progression of PCa, such as 60

interleukin (IL)-6(Deichaite et al., 2022), insulin-like growth factor (IGF)-1 and IGFbinding protein (IGFBP)-1(Cao et al., 2015). However, observational studies
exploring the association between plasma proteins and PCa risk are often limited by
confounding factors and selection bias, making it challenging to establish a clear
causal relationship.

To overcome these limitations, Mendelian randomization (MR) offers a robust methodological approach. This approach utilizes the principle of random assortment of genes from parents to offspring, using genetic variation as an instrumental variable, which mimics the randomization process in a controlled trial, thereby minimizing the impact of reverse causality(Davies, Holmes, & Smith, 2018). With the recent development of proteomics technology, several large-scale proteomic studies have

identified over 18,000 protein quantitative trait loci (pQTLs) covering more than 4800
proteins(Ferkingstad et al., 2021; Pietzner et al., 2021). By using MR, researchers can
gain a deeper comprehension of whether particular plasma proteins hold a causal
nexus with PCa, thereby potentially unraveling novel biomarkers and targets for the
prevention and treatment of PCa.

77 In this study, we performed a meta-analysis of two genome-wide association studies 78 (GWAS) on PCa (PRACTICAL and FinnGen) for a total sample size of 94,397 cases 79 and 192,372 controls. Based on GWAS summary statistics data from deCODE and 80 UKB-PPP cohorts, we further performed a protein-wide MR (PW-MR) study, supplemented by colocalization analysis, to explore the casual relationship between 81 plasma proteins and PCa risk. Moreover, we indicated biological processes and 82 83 pathways associated with PCa, and evaluated the druggability of risk proteins. We aimed to identify novel plasma proteins biomarkers for PCa, which could address the 84 limitations of current diagnostic methods and offer new insights into the biological 85 86 mechanisms of PCa and potential therapeutic targets for intervention.

Results 87

Meta-analysis of the Genome-Wide Association Studies for Prostate Cancer 88

We conducted a meta-analysis combing two GWAS studies with a collective sample 89 size of 94,397 individuals with PCa and 192,372 controls, aiming to identify genetic 90 variants linked to PCa. The associations and assessment of SNPs heterogeneity that 91 92 passed the genome-wide P-value threshold at these loci with PCa were presented in Supplementary Table 1. We found 5 genetic risk loci contained at least one SNP 93 passing the genome-wide significance threshold of P \leq 5×10⁻⁸: JAZF1, PDILM5, 94 WDPCP, EEFSEC, and TNS3 (Figure 1). Among them, PDLIM5, WDPCP, EEFSEC 95 and TNS3 were promising candidates as novel susceptibility loci associated with PCa. 96 Supplementary Figure 1 displayed the associated quantile-quantile plot. The 97 LocusZoom plots of the top SNPs at JAZF1, PDILM5, WDPCP, EEFSEC and TNS3, 98 along with their genomic location, GWAS P values and recombination rate with 99 100 neighboring SNPs were visualized in Supplementary Figure 2. In summary, this GWAS meta-analysis discovered genetic variations in one recognized PC-associated 101 loci and four potential novel loci, providing a reliable dataset for MR analyses. 102

103 **Cross-phenotype Analysis of Prostate Cancer**

104 We used the iCPAGdb to conduct the cross-phenotype genetic association analyses with PCa genome-wide significant SNPs (P $\leq 5 \times 10^{-8}$). The iCPAGdb offered an 105 106 improved algorithm for identifying cross-phenotype associations by using precomputed ancestry-specific LD databases and integrating genetic data from 3793 107 traits in the NHGRI-EBI GWAS catalog(L. Wang et al., 2020). After adjusting for 108

Bonferroni's correction, the cross-phenotype analysis indicated that 117 traits showed 109 significant association with PCa (Supplementary Table 2). As shown in Figure 2, the 110 top 10 enrichments were for prostate specific antigen measurement ($P=7.16\times10^{-43}$), 111 body height (P= 2.18×10^{-30}), BMI-adjusted waist-hip ratio (P= 1.32×10^{-26}), high 112 density lipoprotein cholesterol measurement (P=2.38×10⁻²²), systolic blood pressure 113 (P=2.93×10⁻²²), balding measurement (P=3.01×10⁻²²), leukocyte count (P=3.46×10⁻ 114 ²¹), blood protein measurement (P= 4.95×10^{-21}), body mass index (P= 1.71×10^{-20}) and 115 heel bone mineral density ($P=2.02\times10^{-19}$). 116

117 Proteome-Wide Mendelian Randomization Studies of Prostate Cancer

The genetic association summary statistics of 35,559 Icelanders from deCODE 118 Genetics and 54,219 Europeans from the UKB-PPP were utilized to investigate the 119 120 relationship between PCa and plasma proteins. Our genetic instrument selection strategy enabled us to examine 1778 and 1944 proteins from deCODE and UKB-PPP 121 (Supplementary Table 3A and B). Using the Wald ratio or IVW method, a total of 193 122 unique plasma proteins were significantly associated with PCa after multiple tests 123 with a 5% FDR correction. This analysis yielded 137 proteins in UKB-PPP more than 124 76 proteins in deCODE (Figure 3A). The results of Heterogeneity test based on Q 125 126 statistics showed little evidence of heterogeneity. Furthermore, no significant intercept was detected, implying that there was no directional pleiotropy observed. 127 After FDR correction, 20 proteins were detected in both data sets and the identified 128

129 After FDR correction, 20 proteins were detected in both data sets and the identified
129 associations were consistent (Figure 3B). Genetic prediction indicated that 11 of these
130 20 proteins were positively associated with the risk of PCa as well as remaining 9

131	proteins were negatively associated, suggesting that these 9 proteins maybe protective
132	factors against PCa (Supplementary Table 4). A PhenoGram depicted the
133	chromosomal location of the 193 unique identified proteins in deCODE and UKB-
134	PPP studies (Figure 3C).
135	Colocalization analysis
136	We performed colocalization analyses of proteins significantly expressed in deCODE
137	and UKB-PPP studies with PCa. It was observed that 4 proteins in deCODE study and
138	7 proteins in UKB-PPP were colocalized with PCa associations with high support of
139	evidence (PPH4 \ge 0.8) (Table 1), suggesting that these 10 plasma proteins might serve
140	as potential targets for treating PCa. Among them, SERPINA3 showed strong
141	colocalization evidence in both decode (PPH4=0.952) and UKB-PPP (PPH4=0.951)
142	studies. This analysis identified 1 causal variant in deCODE (rs61976125) and 1
143	causal variant in Fenland (rs6575449) (Figure 4).

Т	able 1	. Analy	vsis of	f Mendelian	randomization	1 and co	localizati	ion of	signi	ficant	proteins	with J	PCa.
-			,								p100001110		

GWAS	Outcomes	Proteins		Colocalization		
			OR (95%CI)	P value	P value after FDR adjustment	Analysis PH4
deCODE	Prostate Cancer	MSMB	0.86(0.84,0.88)	1.56E-27	2.82E-24	0.999
		POGLUT3	0.89(0.83,0.96)	1.16E-03	2.44E-02	0.998
		PRSS3	0.93(0.91,0.94)	1.00E-18	6.03E-16	0.956
		SERPINA3	1.11(1.06,1.15)	7.18E-08	1.05E-05	0.952
UKB-PPP	Prostate Cancer	USP28	0.47(0.40,0.56)	7.27E-17	2.89E-14	0.999
		KLK3	9.70(4.94,19.03)	3.83E-11	6.91E-09	0.999
		IGFBP3	1.07(1.05,1.09)	2.04E-11	4.49E-09	0.997
		CASP10	1.22(1.11,1.34)	4.73E-05	1.54E-03	0.988
		HDGF	0.96(0.95,0.97)	2.61E-17	1.29E-14	0.966
		SERPINA3	1.10(1.07,1.13)	1.64E-10	2.32E-08	0.951
		C5	1.19(1.11,1.27)	5.32E-07	4.06E-05	0.883

145 OR, odds ratio; CI, confidence interval; FDR, false discovery rate.

146 Gene-Based Association and Pathway Analyses

We used the GENE2FUNC tool available in FUMA to explore the biological 147 significance, functional implications and tissue-specific expression of the genes 148 identified from our GWAS. These genes appeared to be significantly enriched in 149 inflammatory and immune pathways (such as defense, immune and inflammatory 150 151 response), as well as cell interaction and signaling pathways (such as interaction 152 between organism and cell adhesion) (Figure 5A). The KEGG pathway enrichment analysis revealed several pathways that were significantly enriched, such as cytokine-153 cytokine receptor interaction, p53 signaling pathway, JAK-STAT signaling pathway, 154 pathways in cancer and apoptosis (Figure 5B). These analyses indicated potential 155 biological processes and mechanisms associated with PCa. The 193 unique genes 156 157 were predominantly expressed in the lymphocytes, blood, liver and prostate (Supplementary Figure 3). 158

159 Druggability of identified proteins

Exploring new therapeutic opportunities for PCa based on genetic information is 160 crucial for developing targeted treatments. In our study, we examined the druggability 161 of genes and proteins identified in MR analyses using OpenTargets databases. We 162 163 investigated 128 unique drugs targeting 45 identified proteins (Supplementary Table 5). Among these, three drugs (APATORSEN, TRIAPINE and MK-4721) currently in 164 clinical trials were intended for PCa treatment, with each targeting HSPB1, RRM2B 165 and PSCA, respectively. Notably, the effects of these drugs on their respective protein 166 167 targets align with the directions indicated by our MR results, suggesting a consistency

168	between genetic evidence and therapeutic potential. In addition, several other
169	identified targets, such as RET, FGFR3, NCAM1, TYMP, TNFRSF10B, MMP3,
170	TACSTD2 and NOTCH2, were implicated in various cancers and present potential

171 therapeutic avenues.

172 Discussion

In this study, we conducted a comprehensive meta-analysis of two GWAS for PCa, 173 identifying significant genetic loci associated with PCa risk. The combined sample 174 size of 94,397 cases and 192,372 controls revealed one known (JAZF1) and four 175 potential novel (PDLIM5, WDPCP, EEFSEC and TNS3) susceptibility loci of PCa. 176 177 JAZF1 (Juxtaposed with another zinc finger gene 1) is a transcriptional repressor of 178 testicular nuclear receptor 4 (TR4) (Nakajima, Fujino, Nakanishi, Kim, & Jetten, 2004). Several GWAS studies have implicated that JAZF1 is highly associated with 179 type 2 diabetes and PCa risk(Frayling, Colhoun, & Florez, 2008; Machiela et al., 180 2012; Saxena, Voight, Zeggini, Scott, & Genetics, 2008; Thomas et al., 2008). JAZF1 181 may influence the risk of PCa through its role in metabolic regulation(Rosario et al., 182 183 2023) and cellular proliferation(Sung et al., 2018). PDLIM5 (PDZ and LIM domain 5) is a member of the enigma subfamily and features 184 a N-terminal PDZ domain and three C-terminal LIM domains(X. J. Wang & Su, 185 2010). A study implicated that downregulating the expression of PDLIM5 could 186 ultimately impede the progression of PCa(Xie et al., 2020). WDPCP, a PCP effector, 187 can regulate PCP by directly modulating the actin cytoskeleton(Cui et al., 2013). 188 Disruption of PCP signaling can cause abnormal cell behavior and tissue structure, 189 leading to the development of cancer(Humphries & Mlodzik, 2018). EEFSEC 190 (eukaryotic elongation factor, selenocysteine-tRNA specific) was identified as a 191

192 genome-wide significant loci in recent chronic obstructive pulmonary disease
193 GWAS(Hobbs et al., 2017; Wain et al., 2017). TNS3 (Tensin 3) is involved in cell

migration, invasion and adhesion processes(Chen et al., 2017; Martuszewska et al.,
2009; Zheng et al., 2021; Zuidema et al., 2022), which are critical in cancer
metastasis. To certain whether these 4 genes causative factors for PCa, genetic
association studies with a larger sample size will be needed.

In the cross-phenotype Analysis of PCa, we found that prostate specific antigen (PSA) measurement, BMI-adjusted waist-hip ratio (WHR), high density lipoprotein cholesterol (HDL) measurement, systolic blood pressure, balding measurement and other traits were significantly associated with PCa. These findings highlighted the multifactorial nature of PCa and underscored the importance of considering a broad range of physiological and biochemical factors in understanding its etiology and progression.

PSA measurement, a protein secreted by both normal and malignant prostate epithelial cells, has long been a cornerstone in the early detection and monitoring of PCa(Oesterling, 1991). However, the specificity and sensitivity of PSA as a diagnostic tool have been questioned due to its elevation in benign conditions such as prostatitis and benign prostatic hyperplasia, leading to unnecessary biopsies(Carter et al., 2013) and substantial overdiagnosis(Draisma et al., 2009). Therefore, supplementary biomarkers are urgently needed to improve diagnostic accuracy.

Obesity has emerged as a significant risk factor in cancer development(Petrelli et al.,
2021), such as aggressive PCa(Moyad, 2015). The significant association between
BMI-adjusted WHR and PCa suggested that central obesity may play a critical role in
the development of PCa(Perez-Cornago, Dunneram, Watts, Key, & Travis, 2022).

Central adiposity, primarily referring to visceral adipose tissue, can influence 216 217 inflammatory thereby contributing hormone levels and processes, to carcinogenesis(Doyle, Donohoe, Lysaght, & Reynolds, 2012). HDL cholesterol is 218 known for its atherosclerotic protective effects(Rohatgi, Westerterp, von Eckardstein, 219 Remaley, & Rye, 2021), mainly due to the ability to promote the reverse transport of 220 221 cholesterol from peripheral cells to the liver for excretion(Cuchel & Rader, 2006), and to exert antioxidant and anti-inflammatory activities. Through similar mechanisms, 222 HDL may influence the development and progression of tumors, by directly 223 interacting with cancer cells or by modifying the tumor microenvironment(Ossoli, 224 Wolska, Remaley, & Gomaraschi, 2022). Higher HDL levels might confer a 225 protective effect against PCa by influencing cancer cells proliferation, possibly 226 227 through mechanisms involving antioxidant(Ruscica et al., 2018) and antiinflammatory properties. 228

Results from previous studies of the association between hypertension and PCa 229 development have been inconsistent(Christakoudi et al., 2020; Liang et al., 2016; 230 Seretis et al., 2019). One MR analysis suggested that elevated systolic blood pressure 231 might be linked to an increased risk of PCa, potentially due to systemic 232 inflammation(Stikbakke et al., 2022), which contributed to a pro-tumorigenic 233 environment by promoting cellular proliferation, DNA damage, and resistance to 234 235 apoptosis(Mantovani, Allavena, Sica, & Balkwill, 2008). However, the precise relationship between systolic blood pressure and PCa remains unclear. More research 236 237 is needed to elucidate the exact biological pathways involved and to determine

238 whether managing hypertension could serve as a preventive strategy for PCa.

239 The underlying mechanism for the link between androgenic alopecia and an increased risk of PCa may involve androgen metabolism, as both conditions are influenced by 240 dihydrotestosterone (DHT) levels. Elevated DHT can promote the miniaturization of 241 hair follicle leading to balding(Kaufman, 1996), as well as stimulate prostate cell 242 243 proliferation(Tong et al., 2022), contributing to the development of PCa. While these 244 associations highlight a potential shared hormonal pathway, further studies are needed to confirm the causality. Overall, our cross-phenotype analysis provided a 245 comprehensive view of the diverse factors associated with PCa and enhanced our 246 247 understanding of the disease's multifaceted nature. Future researches should focus on elucidating the underlying mechanisms of these associations and exploring their 248 249 potential for integration into clinical practice.

We performed a PW-MR study supplemented by colocalization analysis to explore the 250 casual association of 3,722 plasma proteins with the risk of PCa. MR analysis 251 identified a total of 193 unique proteins significantly associated with PCa, of which 252 10 proteins had a strong support of colocalization. Microseminoprotein-beta 253 (MSMB), also known as PSP94 or beta-inhibin, as an immunoglobulin superfamily 254 protein and one of the most abundant proteins secreted by prostate epithelial cells has 255 the strongest correlation(Byrne et al., 2019). We predicted that men with lower blood 256 levels of MSMB have higher risk of PCa, based on two European ancestry cancer 257 GWAS studies. These results were consistent with another published prospective 258 study(Haiman et al., 2013), supporting a potential protective role of MSMB in the 259

260 development of PCa. One previous publication reported that the decreased expression of MSMB was both in the tumor (especially in more advanced tumor) and adjacent 261 262 benign prostate tissue(Bergström, Järemo, Nilsson, Adamo, & Bergh, 2018), which is not in conflict as it may be related to aggressiveness of prostate tumors. Although the 263 mechanism of action of MSMB in PCa is unclear, it has been shown to control 264 265 prostate cell growth by regulating apoptosis(Garde et al., 1999). In addition to our 266 study, several other studies also supported the potential of MSMB as a serum marker for the early detection of PCa(Nam et al., 2006; Reeves, Dulude, Panchal, Daigneault, 267 & Ramnani, 2006). Consequently, further research is essential to explore the 268 functional role and possible clinical utility of MSMB in PCa. 269

Serine protease inhibitor A3 (SERPINA3), an inhibitors of serine proteases that 270 271 promotes tumor development by regulating the transcription of some oncogenes and its elevation was associated with a worse prognosis in some cancers(De Mezer et al., 272 273 2023). SERPINA3 was up-regulated in PCa cells and enhanced cells migration and invasion(Z. S. Xing, Li, Liu, Zhang, & Bai, 2021), which was consistent with our 274 prediction of it as a risk factor in this MR Study. A study identified that the enhanced 275 expression of SERPINA3 stimulated the bone environment, therefore it may be served 276 277 as a diagnostic biomarker to predict PCa with bone metastasis phenotype and survival(Ito et al., 2023). 278

279 Protease serine 3 (PRSS3), also named mesotrypsin, is reported to be aberrantly 280 expressed in various types of tumors and participates in the progression and 281 development of cancers. For example, PRSS3 was identified to be downregulated in

282 lung cancer(Zhou, Li, & Luo, 2023) but upregulated in pancreatic cancer(Jiang et al.,

283 2010; C. J. Xing et al., 2019), suggesting it may have different roles depending on the 284 cellular or disease ways. A study of *vivo* and *vitro* experiments has demonstrated that 285 PRSS3 played an important role in PCa metastasis(Hockla et al., 2012). Despite these 286 findings, further studies are necessary to fully understand the functions and 287 mechanisms of PRSS3 in human PCa.

KLK3 (Kallikrein Related Peptidase 3), also known as PSA, is a serine protease 288 predominantly expressed in the prostate gland. One potential mechanism through 289 which KLK3 may influence PCa development involved its proteolytic activity, which 290 can degrade extracellular matrix components and facilitate tumor invasion and 291 metastasis(Avgeris, Mavridis, & Scorilas, 2012; Lawrence, Lai, & Clements, 2010; 292 293 Mavridis, Avgeris, & Scorilas, 2014). Additionally, the androgen regulation of KLK3 expression correlated with the androgen receptor signaling pathway, a critical driver 294 of PCa progression, particularly in castration-resistant prostate cancer (CRPC)(Lilia, 295 Ulmert, & Vickers, 2008). Despite these insights, the precise biological pathways 296 through which KLK3 contributes to PCa progression remain incompletely understood. 297 Further research is needed to illustrate the direct and indirect effects of KLK3 on PCa 298 cells and the tumor microenvironment. 299

Lastly, the druggability evaluation identified 45 protein biomarkers that have been targeted by 128 drugs. Among these, three drugs targeting HSPB1, RRM2B and PSCA, respectively, are currently in clinical trials for potential use in PCa treatment. HSPB1, also known as human HSP27, is a small heat-shock protein that functions as

304 a molecular chaperone, protecting cells against stress-induced damage and apoptosis(Okuno, Adachi, Kozawa, Shimizu, & Yasuda, 2016). It was overexpressed 305 in various cancers(Sheng et al., 2017; Shi et al., 2019), including PCa(Shiota et al., 306 2013; Vasiljevic et al., 2013), and was associated with tumor progression, metastasis 307 and resistance to therapy. Evidences in vitro and in vivo suggested that inhibiting 308 309 HSP27 inhibits tumor growth and sensitivity to cytotoxic chemotherapy(Hadaschik et al., 2008; Kamada et al., 2007). APATORSEN is an antisense oligonucleotide 310 designed to inhibit HSPB1 expression(Jansen & Zangemeister-Wittke, 2002), which 311 is still in clinical trials. 312

RRM2B is a subunit of ribonucleotide reductase, an enzyme critical for DNA 313 synthesis and repair(Okumura et al., 2005). Its expression was upregulated in 314 315 response to DNA damage and was involved in maintaining genomic stability(Aye, Li, Long, & Weiss, 2015; Foskolou et al., 2017). Elevated levels and distinct mutation 316 317 signatures of RRM2B have been linked to poor prognosis in several cancers(Iqbal et 318 al., 2021). PSCA is a cell surface glycoprotein highly expressed in high-grade PCa(Gu et al., 2000; Zhigang & Wenly, 2004) and other solid tumors(Teng et al., 2022), and 319 was involved in cell proliferation, adhesion and survival(Li et al., 2017). 320

This study possessed several strengths, including the use of the largest collection of plasma protein data (coving more than 4800 proteins), large sample sizes of GWAS studies, a mutual validation across two independent outcome datasets and the use of colocalization analysis to support the MR results. Additionally, our assessment of the human blood proteome relied on two technologies (SOMAmer and Olink), which

were valuable for identifying plasma proteins associated with diseases traits such asPCa.

Some limitations of our analysis should be acknowledged. Firstly, this investigation 328 was only confined to Europeans, restricting the applicability of our findings to other 329 330 populations. It is crucial for future studies to identify risk proteins in more diverse 331 populations, especially African ancestry who face a higher risk of PCa. Moreover, our 332 study concentrated on the proteins available in the MR analysis, which likely led to the omission of other potential therapeutic targets. Lastly, we utilized proteomic data 333 from Icelanders whose genetic backgrounds may differ from other European 334 populations, which might introduce bias. However, this potential bias might be 335 minimal, as we found that 20 proteins showing significance (P<0.05) in both the 336 337 deCODE and UKB-PPP studies had consistent associations with PCa.

In conclusion, we conducted a large-scale PW-MR study using the MR and colocalization analysis to investigate the genetic associations of up to 3,722 unique proteins with PCa. We revealed the complex genetic architecture of PCa and identified many new plasma proteins with strong causal associations to PCa. These findings highlighted the potential biomarkers for early detection and therapeutic targets, providing a foundation for future research and potential clinical applications.

344 Methods

345 Data sources for plasma proteins

We selected *cis*-SNPs associated with plasma proteins as instrumental variables from 346 two large-scale GWASs in the deCODE Genetics(Ferkingstad et al., 2021) and UKB-347 PPP(Sun et al., 2023). Cis-SNPs were defined as SNPs within a vicinity of ±1 Mb 348 349 around the gene encoding the protein. From these SNPs, only those with a minor allele frequency of $\geq 1\%$ that were genome-wide significance (p < 5×10^{-8}) and 350 considered independent (linkage disequilibrium $r^2 < 0.1$ in 1000G) were retained. 351 deCODE Genetics conducted proteomic profiling on blood plasma samples from 352 35,559 Icelanders using the SomaScan platform and collected data on 4907 353 aptamers(Ferkingstad et al., 2021). For the two-sample MR analysis, we selected cis-354 SNPs as instrumental variables for 1778 proteins. Likewise, cis-SNPs for 1944 355 plasma proteins were obtained from the UKB-PPP where 2940 proteins were 356 measured among 54,219 Europeans using the Olink platform(Sun et al., 2023). The 357 proteins with positive MR results were included in the colocalization analysis. 358

359 Data sources for Prostate Cancer

GWAS summary statistics for PCa were obtained from the PRACTICAL consortium(Schumacher et al., 2018) and FinnGen study. The PRACTICAL (Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome) consortium included 79,198 cases and 61,106 controls. We used the data on PCa from the FinnGen study R10 in this analysis, which comprised 15,199 cases and 131,266 controls. All participants of these two cohorts were of European ancestry. In

the MR analysis, we treated the PRACTICAL consortium as the discovery study and
the FinnGen R10 study as the replication. To increase the effectiveness, we performed
a fixed-effect GWAS meta-analysis of the two GWASs using the METAL package.
The quantile-quantile plot was generated using the "qqman" package in R software.
The R package "gassocplot" was used to plot regional association plots for the top
SNP at each of the genome-wide significant loci identified.

372 Cross-phenotype analysis

373 Through the interactive Cross-Phenotype Analysis of GWAS database (iCPAGdb)(L.

374 Wang et al., 2020), a new platform for cross-phenotype analysis, we explored the genetic correlation between PCa and other traits. We analyzed the genetic correlations 375 between PCa and 3793 traits using data from the National Human Genome Research 376 377 Institute-European Bioinformatics Institute (NHGRI-EBI) GWAS catalog(L. Wang et al., 2020). Through the use of ancestry LD-specific association data, iCPAGdb 378 379 performs cross-phenotype enrichment analyses. iCPAGdb reveals signals of pairwise 380 traits and shared signals by analyzing traits associations with LD proxy SNPs. The output data will show results from Fisher's exact test with adjustment for 5% false 381 discovery rate (FDR) and also Bonferroni's, Jaccard's, Sorensen's, and Chao-382 Sorensen similarity indexes. 383

384 MR analysis

We conducted a MR analysis with plasma proteins as the exposure variable and PC as the outcome variable. We utilized the R package "TwoSampleMR" in R software (4.3.3) for the MR analysis. When only one SNP was available for a particular

protein, we applied the Wald ratio test. Inverse-variance weighted (IVW) was used as 388 the main analysis method for two or more SNPs available. Considering multiple 389 testing, we employed the 5% False Discovery Rate (FDR) method for P-value 390 correction. P<0.05 was considered statistically significant. MR-Egger and weighted 391 median methods were used as supplementary analysis methods. Cochran's Q statistic 392 393 test using the MR-Egger method was used to determine the heterogeneity between the 394 genetic variants. We also performed MR-Egger regression intercept to detect and adjust the directional horizontal pleiotropy(Hemani, Bowden, & Smith, 2018), P<0.05 395 was considered as the presence of directional pleiotropy and thus removed from the 396 further analyses. 397

398 Colocalization analysis

The "coloc" package was used to perform Bayesian colocalization analysis to 399 investigate if the associations between plasma proteins and PCa were driven by 400 linkage disequilibrium (LD) (Giambartolomei et al., 2014). For proteins with positive 401 MR results, the Bayesian method assessed the support for the following five exclusive 402 hypotheses: 1) no association with either trait; 2) association with trait 1 only; 3) 403 association with trait 2 only; 4) both traits are associated, but distinct causal variants 404 were for two traits; and 5) both traits are associated, and the same shares causal 405 variant for both traits(Foley et al., 2021). The posterior probability is provided for 406 each hypothesis (H0, H1, H2, H3, and H4). In this analysis, we set prior probabilities 407 of the SNP being associated with trait 1 only (p1) at 1×10^{-4} ; the probability of the 408 SNP being associated with trait 2 only (p2) at 1×10^{-4} ; and the probability of the SNP 409

410 being associated with both traits (p12) at 1×10^{-5} . Two signals were considered to 411 have strong evidence of colocalization if the posterior probability for shared causal 412 variants (PH4) was ≥ 0.8 . The analysis was performed in R software (4.3.3).

413 Biological pathway analysis

The GENE2FUNC tool in FUMA(Watanabe, Taskesen, van Bochoven, & Posthuma, 414 415 2017) web application programming interface version 1.5.2 were used to investigate 416 functional annotation and enrichment analysis of the genes coding for the 193 unique proteins identified by the PW-MR approach. This analysis involved calculating the 417 log2 fold-change expression for each gene across 54 tissue types from the GTEx 418 (Genotype-Tissue Expression) database. We conducted gene enrichment analysis to 419 identify overrepresented biological processes using the Gene Ontology (GO) 420 421 database, which helped determine the biological processes most relevant to the genes identified. To investigate the involvement of the identified genes in functional and 422 signaling pathways, we used the KEGG (Kyoto Encyclopedia of Genes and Genomes) 423 pathway database. Enrichment results were considered significant if they passed 5% 424 FDR P-value threshold. Additionally, only enrichments involving at least two 425 overlapping genes with the gene sets were considered to ensure robustness and 426 biological relevance. 427

428 Druggability evaluation

The analysis of drug targets for the significant proteins identified in the MR Analysis
was conducted using data from OpenTargets(Ochoa et al., 2023) (v.22.11), which is
publicly accessible. We selected all drugs for which there was evidence for an

association with the protein of interest. 432

Data availability 433

434	The GWAS summary statistics of blood pQTLs from deCODE can be found at
435	https://www.decode.com/summarydata/, and those of the UKB-PPP can be found at
436	https://www.synapse.org/#!Synapse:syn51365303. Summary statistics of PCa from
437	the PRACTICAL consortium can be obtained from OpenGWAS
438	(https://gwas.mrcieu.ac.uk/), and those of the FinnGen study can be obtained from
439	https://r10.finngen.fi/. The OpenTargets data were downloaded directly from the
440	OpenTargets website (<u>https://platform.opentargets.org/downloads/data</u>).
441	Acknowledgements
442	The authors would like to thank all the participants and investigators of the studies

443 (PRACTICAL, FinnGen, deCODE, UKB-PPP) for providing the invaluable data used

444 in this research. Their commitment and effort have been essential for the success of

this study. Furthermore, special thanks to our colleagues and collaborators for their 445

insightful discussions and feedback throughout the research process. This research 446

was funded by Beijing Municipal Natural Science Foundation (grant No. JQ24059, No. L234038), and National Natural Science Foundation of China (grant No. 448

82274015). 449

447

450 **References**

- 451 Avgeris, M., Mavridis, K., & Scorilas, A. (2012). Kallikrein-related peptidases in
 452 prostate, breast, and ovarian cancers: from pathobiology to clinical relevance.
 453 *Biol Chem*, 393(5), 301-317. doi:10.1515/hsz-2011-0260
- Aye, Y., Li, M., Long, M. J. C., & Weiss, R. S. (2015). Ribonucleotide reductase and
 cancer: biological mechanisms and targeted therapies. *Oncogene*, 34(16),
 2011-2021. doi:10.1038/onc.2014.155
- Bergström, S. H., Järemo, H., Nilsson, M., Adamo, H. H., & Bergh, A. (2018).
 Prostate tumors downregulate microseminoprotein-beta (MSMB) in the
 surrounding benign prostate epithelium and this response is associated with
 tumor aggressiveness. *Prostate*, 78(4), 257-265. doi:10.1002/pros.23466
- Byrne, K. S., Appleby, P. N., Key, T. J., Holmes, M. V., Fensom, G. K., Agudo, A., ...
 Consortium, P. (2019). The role of plasma microseminoprotein-beta in prostate
 cancer: an observational nested case-control and Mendelian randomization
 study in the European prospective investigation into cancer and nutrition. *Annals of Oncology, 30*(6), 983-989. doi:10.1093/annonc/mdz121
- Cao, Y., Nimptsch, K., Shui, I. M., Platz, E. A., Wu, K., Pollak, M. N., . . .
 Giovannucci, E. L. (2015). Prediagnostic plasma IGFBP-1, IGF-1 and risk of
 prostate cancer. *International Journal of Cancer*, *136*(10), 2418-2426.
 doi:10.1002/ijc.29295
- 470 Carter, H. B., Albertsen, P. C., Barry, M. J., Etzioni, R., Freedland, S. J., Greene, K.
 471 L., . . Zietman, A. L. (2013). Early Detection of Prostate Cancer: AUA
 472 Guideline. *Journal of Urology, 190*(2), 419-426.
 473 doi:10.1016/j.juro.2013.04.119
- Chen, H. Y., Lin, L. T., Wang, M. L., Laurent, B., Hsu, C. H., Pan, C. M., . . . Chiou,
 S. H. (2017). Musashi-1 Enhances Glioblastoma Cell Migration and
 Cytoskeletal Dynamics through Translational Inhibition of Tensin3. *Scientific Reports*, 7, 14. doi:10.1038/s41598-017-09504-7
- 478 Christakoudi, S., Kakourou, A., Markozannes, G., Tzoulaki, I., Weiderpass, E.,

Brennan, P., . . . Tsilidis, K. K. (2020). Blood pressure and risk of cancer in the
European Prospective Investigation into Cancer and Nutrition. *Int J Cancer*, *146*(10), 2680-2693. doi:10.1002/ijc.32576

- 482 Cuchel, M., & Rader, D. J. (2006). Macrophage reverse cholesterol transport: key to
 483 the regression of atherosclerosis? *Circulation*, *113*(21), 2548-2555.
 484 doi:10.1161/circulationaha.104.475715
- Cui, C., Chatterjee, B., Lozito, T. P., Zhang, Z., Francis, R. J., Yagi, H., . . . Lo, C. W.
 (2013). Wdpcp, a PCP Protein Required for Ciliogenesis, Regulates
 Directional Cell Migration and Cell Polarity by Direct Modulation of the Actin
 Cytoskeleton. *Plos Biology*, *11*(11), 17. doi:10.1371/journal.pbio.1001720
- 489 Davies, N. M., Holmes, M. V., & Smith, G. D. (2018). Reading Mendelian
 490 randomisation studies: a guide, glossary, and checklist for clinicians. *Bmj-*491 *British Medical Journal, 362*, 11. doi:10.1136/bmj.k601
- De Mezer, M., Rogalinski, J., Przewozny, S., Chojnicki, M., Niepolski, L., Sobieska,
 M., & Przystanska, A. (2023). SERPINA3: Stimulator or Inhibitor of
 Pathological Changes. *Biomedicines*, *11*(1), 15.
 doi:10.3390/biomedicines11010156
- Deichaite, I., Sears, T. J., Sutton, L., Rebibo, D., Morgan, K., Nelson, T., . . . Carter,
 H. (2022). Differential regulation of TNFα and IL-6 expression contributes to
 immune evasion in prostate cancer. *Journal of Translational Medicine*, 20(1),
 16. doi:10.1186/s12967-022-03731-x
- Doyle, S. L., Donohoe, C. L., Lysaght, J., & Reynolds, J. V. (2012). Visceral obesity,
 metabolic syndrome, insulin resistance and cancer. *Proc Nutr Soc*, 71(1), 181189. doi:10.1017/s002966511100320x
- Draisma, G., Etzioni, R., Tsodikov, A., Mariotto, A., Wever, E., Gulati, R., . . . de
 Koning, H. (2009). Lead Time and Overdiagnosis in Prostate-Specific Antigen
 Screening: Importance of Methods and Context. *Jnci-Journal of the National Cancer Institute, 101*(6), 374-383. doi:10.1093/jnci/djp001
- Ferkingstad, E., Sulem, P., Atlason, B. A., Sveinbjornsson, G., Magnusson, M. I.,
 Styrmisdottir, E. L., . . . Stefansson, K. (2021). Large-scale integration of the

511 Ferlay J, E. M., Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, Znaor A,
512 Soerjomataram I, Bray F . (2024). Global Cancer Observatory: Cancer Today.

513 Retrieved from <u>https://gco.iarc.who.int/today</u>

- Foley, C. N., Staley, J. R., Breen, P. G., Sun, B. B., Kirk, P. D. W., Burgess, S., &
 Howson, J. M. M. (2021). A fast and efficient colocalization algorithm for
 identifying shared genetic risk factors across multiple traits. *Nature Communications*, 12(1), 18. doi:10.1038/s41467-020-20885-8
- Foskolou, I. P., Jorgensen, C., Leszczynska, K. B., Olcina, M. M., Tarhonskaya, H.,
 Haisma, B., . . . Hammond, E. M. (2017). Ribonucleotide Reductase Requires
 Subunit Switching in Hypoxia to Maintain DNA Replication. *Molecular Cell*, *66*(2), 206-+. doi:10.1016/j.molcel.2017.03.005
- Frayling, T. M., Colhoun, H., & Florez, J. C. (2008). A genetic link between type 2
 diabetes and prostate cancer Commentary. *Diabetologia*, *51*(10), 1757-1760.
 doi:10.1007/s00125-008-1114-9
- Garde, S. V., Basrur, V. S., Li, L., Finkelman, M. A., Krishan, A., Wellham, L., . . .
 Tang, D. G. (1999). Prostate secretory protein (PSP94) suppresses the growth
 of androgen-independent prostate cancer cell line (PC3) and xenografts by
 inducing apoptosis. *Prostate*, 38(2), 118-125. doi:10.1002/(sici)10970045(19990201)38:2<118::Aid-pros5>3.0.Co;2-g
- Giambartolomei, C., Vukcevic, D., Schadt, E. E., Franke, L., Hingorani, A. D.,
 Wallace, C., & Plagnol, V. (2014). Bayesian Test for Colocalisation between
 Pairs of Genetic Association Studies Using Summary Statistics. *Plos Genetics*, *10*(5), 15. doi:10.1371/journal.pgen.1004383
- Gu, Z., Thomas, G., Yamashiro, J., Shintaku, I. P., Dorey, F., Raitano, A., . . . Reiter,
 R. E. (2000). Prostate stem cell antigen (PSCA) expression increases with high
 gleason score, advanced stage and bone metastasis in prostate cancer. *Oncogene, 19*(10), 1288-1296. doi:10.1038/sj.onc.1203426
- 538 Hadaschik, B. A., Jackson, J., Fazli, L., Zoubeidi, A., Burt, H. M., Gleave, M. E., &

⁵⁰⁹ plasma proteome with genetics and disease. *Nature Genetics*, 53(12), 1712-+.
510 doi:10.1038/s41588-021-00978-w

539	So, A. I. (2008). Intravesically administered antisense oligonucleotides
540	targeting heat-shock protein-27 inhibit the growth of non-muscle-invasive
541	bladder cancer. Bju International, 102(5), 610-616. doi:10.1111/j.1464-
542	410X.2008.07669.x
543	Haiman, C. A., Stram, D. O., Vickers, A. J., Wilkens, L. R., Braun, K., Valtonen-
544	André, C., Lilja, H. (2013). Levels of Beta-Microseminoprotein in Blood
545	and Risk of Prostate Cancer in Multiple Populations. Jnci-Journal of the
546	National Cancer Institute, 105(3), 237-243. doi:10.1093/jnci/djs486
547	Hemani, G., Bowden, J., & Smith, G. D. (2018). Evaluating the potential role of
548	pleiotropy in Mendelian randomization studies. Human Molecular Genetics,
549	27(R2), R195-R208. doi:10.1093/hmg/ddy163
550	Hobbs, B. D., de Jong, K., Lamontagne, M., Bossé, Y., Shrine, N., Artigas, M. S.,
551	Int, C. G. C. (2017). Genetic loci associated with chronic obstructive
552	pulmonary disease overlap with loci for lung function and pulmonary fibrosis.
553	Nature Genetics, 49(3), 426-432. doi:10.1038/ng.3752
554	Hockla, A., Miller, E., Salameh, M. A., Copland, J. A., Radisky, D. C., & Radisky, E.
555	S. (2012). PRSS3/Mesotrypsin Is a Therapeutic Target for Metastatic Prostate
556	Cancer. Molecular Cancer Research, 10(12), 1555-1566. doi:10.1158/1541-
557	7786.Mcr-12-0314
558	Humphries, A. C., & Mlodzik, M. (2018). From instruction to output: Wnt/PCP

- signaling in development and cancer. *Current Opinion in Cell Biology*, 51,
 110-116. doi:10.1016/j.ceb.2017.12.005
- Iqbal, W., Demidova, E. V., Serrao, S., ValizadehAslani, T., Rosen, G., & Arora, S.
 (2021). RRM2B Is Frequently Amplified Across Multiple Tumor Types:
 Implications for DNA Repair, Cellular Survival, and Cancer Therapy. *Frontiers in Genetics*, 12, 13. doi:10.3389/fgene.2021.628758
- Ito, K., Yamamoto, T., Hayashi, Y., Sato, S., Nakayama, J., Urabe, F., . . . Yamamoto,
 Y. (2023). Osteoblast-derived extracellular vesicles exert osteoblastic and
 tumor-suppressive functions via SERPINA3 and LCN2 in prostate cancer. *Molecular Oncology*, 17(10), 2147-2167. doi:10.1002/1878-0261.13484

569	James, N. D., Tannock, I., N'Dow, J., Feng, F., Gillessen, S., Ali, S. A., Xie, LP.
570	(2024). The Lancet Commission on prostate cancer: planning for the surge in
571	cases. Lancet (London, England), 403(10437), 1683-1722. doi:10.1016/s0140-
572	6736(24)00651-2
573	Jansen, B., & Zangemeister-Wittke, U. (2002). Antisense therapy for cancer - the time
574	of truth. Lancet Oncology, 3(11), 672-683. doi:10.1016/s1470-2045(02)00903-
575	8
576	Jiang, G. Z., Cao, F. Y., Ren, G. P., Gao, D. L., Bhakta, V., Zhang, Y. H., Wang, Y.
577	H. (2010). PRSS3 promotes tumour growth and metastasis of human
578	pancreatic cancer. Gut, 59(11), 1535-1544. doi:10.1136/gut.2009.200105
579	Kamada, M., So, A., Muramaki, M., Rocchi, P., Beraldi, E., & Gleave, M. (2007).
580	Hsp27 knockdown using nucleotide-based therapies inhibit tumor growth and
581	enhance chemotherapy in human bladder cancer cells. Molecular Cancer
582	Therapeutics, 6(1), 299-308. doi:10.1158/1535-7163.Mct-06-0417

- 583 Kaufman, K. D. (1996). Androgen metabolism as it affects hair growth in
 584 androgenetic alopecia. *Dermatol Clin, 14*(4), 697-711. doi:10.1016/s0733585 8635(05)70396-x
- Lawrence, M. G., Lai, J., & Clements, J. A. (2010). Kallikreins on steroids: structure,
 function, and hormonal regulation of prostate-specific antigen and the
 extended kallikrein locus. *Endocr Rev, 31*(4), 407-446. doi:10.1210/er.20090034
- Li, E. M., Liu, L. H., Li, F. T., Luo, L. M., Zhao, S. K., Wang, J. M., . . . Zhao, Z. G.
 (2017). PSCA promotes prostate cancer proliferation and cell-cycle
 progression by up-regulating c-Myc. *Prostate*, 77(16), 1563-1572.
 doi:10.1002/pros.23432
- Liang, Z., Xie, B., Li, J., Wang, X., Wang, S., Meng, S., . . . Xie, L. (2016).
 Hypertension and risk of prostate cancer: a systematic review and metaanalysis. *Scientific Reports*, *6*, 31358. doi:10.1038/srep31358
- 597 Lilja, H., Ulmert, D., & Vickers, A. J. (2008). Prostate-specific antigen and prostate
 598 cancer: prediction, detection and monitoring. *Nat Rev Cancer*, 8(4), 268-278.

599 doi:10.1038/nrc2351

- Machiela, M. J., Lindström, S., Allen, N. E., Haiman, C. A., Albanes, D., Barricarte,
 A., . . . Kraft, P. (2012). Association of Type 2 Diabetes Susceptibility Variants
 With Advanced Prostate Cancer Risk in the Breast and Prostate Cancer Cohort
 Consortium. *American Journal of Epidemiology*, *176*(12), 1121-1129.
 doi:10.1093/aje/kws191
- Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008). Cancer-related
 inflammation. *Nature*, 454(7203), 436-444. doi:10.1038/nature07205
- Martuszewska, D., Ljungberg, B., Johansson, M., Landberg, G., Oslakovic, C.,
 Dahlbäck, B., & Hafizi, S. (2009). Tensin3 Is a Negative Regulator of Cell
 Migration and All Four Tensin Family Members Are Downregulated in
 Human Kidney Cancer. *Plos One*, 4(2), 13. doi:10.1371/journal.pone.0004350
- Mavridis, K., Avgeris, M., & Scorilas, A. (2014). Targeting kallikrein-related
 peptidases in prostate cancer. *Expert Opin Ther Targets, 18*(4), 365-383.
 doi:10.1517/14728222.2014.880693
- Moyad, M. A. (2015). Preventing aggressive prostate cancer with proven
 cardiovascular disease preventive methods. *Asian J Androl, 17*(6), 874-877;
 discussion 876. doi:10.4103/1008-682x.156854
- Nakajima, T., Fujino, S., Nakanishi, G., Kim, Y. S., & Jetten, A. M. (2004). TIP27: a
 novel repressor of the nuclear orphan receptor TAK1/TR4. *Nucleic Acids Research, 32*(14), 4194-4204. doi:10.1093/nar/gkh741
- Nam, R. K., Reeves, J. R., Toi, A., Dulude, H., Trachtenberg, J., Emami, M., . . .
 Narod, S. A. (2006). A novel serum marker, total prostate secretory protein of
 94 amino acids, improves prostate cancer detection and helps identify high
 grade cancers at diagnosis. *Journal of Urology*, *175*(4), 1291-1297.
 doi:10.1016/s0022-5347(05)00695-6
- Ochoa, D., Hercules, A., Carmona, M., Suveges, D., Baker, J., Malangone, C., . . .
 McDonagh, E. (2023). The next-generation Open Targets Platform:
 reimagined, redesigned, rebuilt. *Nucleic Acids Research*, 51(D1), D1353D1359. doi:10.1093/nar/gkac1046

Oesterling, J. E. (1991). PROSTATE SPECIFIC ANTIGEN - A CRITICALASSESSMENT OF THE MOST USEFUL TUMOR-MARKER FOR
ADENOCARCINOMA OF THE PROSTATE. *Journal of Urology*, 145(5),
907-923. doi:10.1016/s0022-5347(17)38491-4

- Okumura, H., Natsugoe, S., Matsumoto, M., Mataki, Y., Takatori, H., Ishigami, S., . . .
 Aikou, T. (2005). The predictive value of p53, p53R2, and p21 for the effect of
 chemoradiation therapy on oesophageal squamous cell carcinoma. *British Journal of Cancer*, 92(2), 284-289. doi:10.1038/sj.bjc.6602322
- Okuno, M., Adachi, S., Kozawa, O., Shimizu, M., & Yasuda, I. (2016). The Clinical
 Significance of Phosphorylated Heat Shock Protein 27 (HSPB1) in Pancreatic
 Cancer. *International Journal of Molecular Sciences*, 17(1), 7.
 doi:10.3390/ijms17010137
- Ossoli, A., Wolska, A., Remaley, A. T., & Gomaraschi, M. (2022). High-density
 lipoproteins: A promising tool against cancer. *Biochim Biophys Acta Mol Cell Biol Lipids, 1867*(1), 159068. doi:10.1016/j.bbalip.2021.159068
- Perez-Cornago, A., Dunneram, Y., Watts, E. L., Key, T. J., & Travis, R. C. (2022).
 Adiposity and risk of prostate cancer death: a prospective analysis in UK
 Biobank and meta-analysis of published studies. *Bmc Medicine, 20*(1), 13.
 doi:10.1186/s12916-022-02336-x
- Petrelli, F., Cortellini, A., Indini, A., Tomasello, G., Ghidini, M., Nigro, O., . . .
 Zaniboni, A. (2021). Association of Obesity With Survival Outcomes in
 Patients With Cancer A Systematic Review and Meta-analysis. *Jama Network Open*, 4(3), 30. doi:10.1001/jamanetworkopen.2021.3520
- Pietzner, M., Wheeler, E., Carrasco-Zanini, J., Cortes, A., Koprulu, M., Wörheide, M.
 A., . . Langenberg, C. (2021). Mapping the proteo-genomic convergence of
 human diseases. *Science*, 374(6569), 839-+. doi:10.1126/science.abj1541
- Reeves, J. R., Dulude, H., Panchal, C., Daigneault, L., & Ramnani, D. M. (2006).
 Prognostic value of prostate secretory protein of 94 amino acids and its
 binding protein after radical prostatectomy. *Clinical Cancer Research*, *12*(20),
 6018-6022. doi:10.1158/1078-0432.Ccr-06-0625

659 Rohatgi, A., Westerterp, M., von Eckardstein, A., Remaley, A., & Rye, K. A. (2021).

- HDL in the 21st Century: A Multifunctional Roadmap for Future HDL
 Research. *Circulation*, 143(23), 2293-2309.
 doi:10.1161/circulationaha.120.044221
- Rosario, S. R., Jacobi, J. J., Long, M. D., Affronti, H. C., Rowsam, A. M., &
 Smiraglia, D. J. (2023). JAZF1: A Metabolic Regulator of Sensitivity to a
 Polyamine-Targeted Therapy. *Molecular Cancer Research, 21*(1), 24-35.
 doi:10.1158/1541-7786.Mcr-22-0316
- Ruscica, M., Botta, M., Ferri, N., Giorgio, E., Macchi, C., Franceschini, G., . . .
 Gomaraschi, M. (2018). High Density Lipoproteins Inhibit Oxidative StressInduced Prostate Cancer Cell Proliferation. *Scientific Reports, 8*(1), 2236.
 doi:10.1038/s41598-018-19568-8
- Saxena, R., Voight, B. F., Zeggini, E., Scott, L. J., & Genetics, I. C. D. (2008). Metaanalysis of genome-wide association data and large-scale replication identifies
 several additional susceptibility loci for type 2 diabetes. *Diabetes*, *57*, A41A41. Retrieved from <Go to ISI>://WOS:000256612000133
- Schumacher, F. R., Al Olama, A. A., Berndt, S. I., Benlloch, S., Ahmed, M., Saunders,
 E. J., . . . Elucidating Loci Involved, P. (2018). Association analyses of more
 than 140,000 men identify 63 new prostate cancer susceptibility loci. *Nature Genetics*, 51(2), 363-363. doi:10.1038/s41588-018-0330-6
- 679 Seretis, A., Cividini, S., Markozannes, G., Tseretopoulou, X., Lopez, D. S., Ntzani, E.
 680 E., & Tsilidis, K. K. (2019). Association between blood pressure and risk of
 681 cancer development: a systematic review and meta-analysis of observational
 682 studies. *Scientific Reports*, 9(1), 8565. doi:10.1038/s41598-019-45014-4
- Sheng, B. W., Qi, C. C., Liu, B., Lin, Y., Fu, T., & Zeng, Q. D. (2017). Increased 683 HSP27 correlates with malignant biological behavior of non-small cell lung 684 survival. Scientific 685 cancer and predicts patient's Reports, 7, 12. doi:10.1038/s41598-017-13956-2 686
- Shi, D. B., Ma, R. R., Zhang, H., Hou, F., Guo, X. Y., & Gao, P. (2019). GAGE7B
 promotes tumor metastasis and growth via activating the

p38/pMAPKAPK2/pHSP27 pathway in gastric cancer. Journal of *Experimental & Clinical Cancer Research*, 38, 12. doi:10.1186/s13046-0191125-z

- Shiota, M., Bishop, J. L., Nip, K. M., Zardan, A., Takeuchi, A., Cordonnier, T., . . .
 Zoubeidi, A. (2013). Hsp27 Regulates Epithelial Mesenchymal Transition,
 Metastasis, and Circulating Tumor Cells in Prostate Cancer. *Cancer Research*, *73*(10), 3109-3119. doi:10.1158/0008-5472.Can-12-3979
- Stikbakke, E., Schirmer, H., Knutsen, T., Støyten, M., Wilsgaard, T., Giovannucci, E.
 L., . . . Thune, I. (2022). Systolic and diastolic blood pressure, prostate cancer
 risk, treatment, and survival. The PROCA-life study. *Cancer Med, 11*(4),
 1005-1015. doi:10.1002/cam4.4523
- Sun, B. B., Chiou, J., Traylor, M., Benner, C., Hsu, Y. H., Richardson, T. G., . . .
 Whelan, C. D. (2023). Plasma proteomic associations with genetics and health
 in the UK Biobank. *Nature*, 622(7982), 329-338. doi:10.1038/s41586-02306592-6
- Sung, Y., Park, S., Park, S. J., Jeong, J., Choi, M., Lee, J., . . . Kim, M. O. (2018).
 Jazf1 promotes prostate cancer progression by activating JNK/Slug. *Oncotarget*, 9(1), 755-765. doi:10.18632/oncotarget.23146
- Teng, K. Y., Mansour, A. G., Zhu, Z., Li, Z. Y., Tian, L., Ma, S. B., . . . Yu, J. H.
 (2022). Off-the-Shelf Prostate Stem Cell Antigen-Directed Chimeric Antigen
 Receptor Natural Killer Cell Therapy to Treat Pancreatic Cancer. *Gastroenterology*, 162(4), 1319-1333. doi:10.1053/j.gastro.2021.12.281
- Thomas, G., Jacobs, K. B., Yeager, M., Kraft, P., Wacholder, S., Orr, N., . . . Chanock,
 S. J. (2008). Multiple loci identified in a genome-wide association study of
 prostate cancer. *Nature Genetics*, 40(3), 310-315. doi:10.1038/ng.91
- Tong, Y., Guo, Y. J., Zhang, Q., Bi, H. X., Kai, K., & Zhou, R. Y. (2022). Combined
 treatment with dihydrotestosterone and lipopolysaccharide modulates prostate
 homeostasis by upregulating TNF-α from M1 macrophages and promotes
 proliferation of prostate stromal cells. *Asian J Androl, 24*(5), 513-520.
 doi:10.4103/aja2021114

Vasiljevic, N., Ahmad, A. S., Beesley, C., Thorat, M. A., Fisher, G., Berney, D.
M., . . . Lorincz, A. T. (2013). Association between DNA methylation of
<i>HSPB1</i> and death in low Gleason score prostate cancer. *Prostate Cancer and Prostatic Diseases, 16*(1), 35-40. doi:10.1038/pcan.2012.47

- Wain, L. V., Shrine, N., Artigas, M. S., Erzurumluoglu, A. M., Noyvert, B., BossiniCastillo, L., . . . Geisinger-Regeneron Discov, E. H. R. (2017). Genome-wide
 association analyses for lung function and chronic obstructive pulmonary
 disease identify new loci and potential druggable targets. *Nature Genetics*,
 49(3), 416-425. doi:10.1038/ng.3787
- Wang, L., Balmat, T. J., Antonia, A. L., Constantine, F. J., Henao, R., Burke, T.
 W., . . . Ko, D. C. (2020). An atlas connecting shared genetic architecture of
 human diseases and molecular phenotypes provides insight into COVID-19
 susceptibility. *medRxiv : the preprint server for health sciences*.
 doi:10.1101/2020.12.20.20248572
- Wang, X. J., & Su, H. B. (2010). Unraveling Enigma in the Z-Disk. *Circulation Research*, 107(3), 321-323. doi:10.1161/circresaha.110.225615
- Watanabe, K., Taskesen, E., van Bochoven, A., & Posthuma, D. (2017). Functional
 mapping and annotation of genetic associations with FUMA. *Nature Communications*, 8, 11. doi:10.1038/s41467-017-01261-5
- Xie, P. B., Liu, M. S., Chen, F., Wu, S. M., Shao, T., Wang, W., . . . Zhou, H. Q.
 (2020). Long Non-coding RNA AGAP2-AS1 Silencing Inhibits PDLIM5
 Expression Impeding Prostate Cancer Progression<i>via</i>Up-Regulation of
 MicroRNA-195-5p. *Frontiers in Genetics, 11*, 13.
 doi:10.3389/fgene.2020.01030
- Xing, C. J., Ye, H., Wang, W. W., Sun, M. M., Zhang, J. Y., Zhao, Z. H., & Jiang, G.
 Z. (2019). Circular RNA ADAM9 facilitates the malignant behaviours of
 pancreatic cancer by sponging miR-217 and upregulating PRSS3 expression. *Artificial Cells Nanomedicine and Biotechnology*, 47(1), 3920-3928.
 doi:10.1080/21691401.2019.1671856
- 748 Xing, Z. S., Li, S. L., Liu, Z. X., Zhang, C., & Bai, Z. M. (2021). CircSERPINA3

749 regulates SERPINA3-mediated apoptosis, autophagy and aerobic glycolysis of 750 prostate cancer cells by competitively binding to MiR-653-5p and recruiting 751 BUD13. Journal of Translational Medicine, 19(1), 13. doi:10.1186/s12967-

021-03063-2 752

- 753 Zheng, J. Y., Wang, C. Y., Gao, C., Xiao, Q., Huang, C. W., Wu, M., & Li, L. Y. (2021). MLL3 suppresses tumorigenesis through regulating TNS3 enhancer 754 activity. Cell Death & Disease, 12(4), 13. doi:10.1038/s41419-021-03647-2 755
- Zhigang, Z., & Wenlv, S. (2004). Prostate stem cell antigen (PSCA) expression in 756 human prostate cancer tissues and its potential role in prostate carcinogenesis 757 and progression of prostate cancer. World journal of surgical oncology, 2, 13. 758 doi:10.1186/1477-7819-2-13 759
- 760 Zhou, M. Y., Li, K. K., & Luo, K. Q. (2023). Shear Stress Drives the Cleavage 761 Activation of Protease-Activated Receptor 2 by PRSS3/Mesotrypsin to Promote Invasion and Metastasis of Circulating Lung Cancer Cells. Advanced 762 Science, 10(25), 21. doi:10.1002/advs.202301059 763
- Zuidema, A., Atherton, P., Kreft, M., Hoekman, L., Bleijerveld, O. B., Nagaraj, 764 765 N., . . . Sonnenberg, A. (2022). PEAK1 Y635 phosphorylation regulates cell migration through association with Tensin3 and integrins. Journal of Cell 766 767 *Biology*, 221(8), 18. doi:10.1083/jcb.202108027

Graphical abstract:





Figure 1. Manhattan plot of PCa GWAS meta-analysis. The genetic regions containing top SNPs related to PCa are depicted. The red dashed line signifies the genome-wide significance threshold of 5.0×10^{-8} .



Figure 2. The top 10 significant cross-phenotype associations with PCa at a 5% FDR. The x-axis represents the P value of the correlation. BMI, body mass index.



Figure 3. Result of PW-MR on the associations between plasma proteins and the risk of PCa. (A) Volcano plot of PCa PW-MR study using deCODE (the left side) and UKB-PPP (the right side) cohorts. Annotated proteins passed the 5% FDR IVW P-value threshold. The blue and red colors represent a negative and positive effect, respectively. (B) Venn diagram depicting proteins associated with PCa in deCODE and UKB-PPP. (C) PhenoGram of PCa PW-MR study significant associations. The blue dots and the green dots represent the deCODE and UKB-PPP specific proteins, respectively. The red dot represents both simultaneously.

medRxiv preprint doi: https://doi.org/10.1101/2024.09.17.24312688; this version posted September 18, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .



Figure 4. Colocalization plot of SERPINA3 variants associated with PCa in deCODE and UKB-PPP. Variants are color-coded based on their linkage disequilibrium (LD) with the lead SNP (the variant with the lowest p-value). The lead SNP is highlighted in red. Other variants are colored from blue to yellow, indicating decreasing LD with the lead SNP.



Figure 5. Functional annotation of the genetic architecture of PCa. (A) Biological processes and (B) KEGG pathway analysis of the 193 unique proteins identified in deCODE and UKB-PPP.